Earnings call transcript: IRIDEX misses Q2 2026 estimates as cash flow turns positive
IRIDEX Corp. reported a wider-than-expected loss and lower-than-forecast revenue for Q2 2026. The ophthalmic device maker posted a loss of 7 cents per share, surpassing analysts' expectations for a 2-cent loss. Revenue was $12.6 million, missing the consensus estimate of $14.13 million. Shares initially rose 5.69% before falling 4.31% after hours. The company achieved positive operating cash flow for the first time, attributed to tighter cost control and better working-capital management.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
